|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NPTXR |
Gene summary for NPTXR |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NPTXR | Gene ID | 23467 |
| Gene name | neuronal pentraxin receptor | |
| Gene Alias | NPR | |
| Cytomap | 22q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | O95502 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23467 | NPTXR | HCC1 | Human | Liver | HCC | 2.10e-06 | 7.39e-01 | 0.5336 |
| 23467 | NPTXR | HCC2 | Human | Liver | HCC | 2.13e-19 | 1.47e+00 | 0.5341 |
| 23467 | NPTXR | HCC5 | Human | Liver | HCC | 7.01e-20 | 1.11e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NPTXR | SNV | Missense_Mutation | novel | c.1420C>T | p.Pro474Ser | p.P474S | O95502 | protein_coding | tolerated(0.21) | probably_damaging(0.979) | TCGA-CX-7086-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| NPTXR | SNV | Missense_Mutation | novel | c.915N>A | p.Met305Ile | p.M305I | O95502 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
| NPTXR | SNV | Missense_Mutation | rs764050642 | c.961G>A | p.Ala321Thr | p.A321T | O95502 | protein_coding | tolerated(0.07) | benign(0.013) | TCGA-BR-8078-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NPTXR | SNV | Missense_Mutation | novel | c.682C>T | p.Pro228Ser | p.P228S | O95502 | protein_coding | tolerated(0.32) | probably_damaging(0.954) | TCGA-BR-8368-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NPTXR | SNV | Missense_Mutation | c.1243A>G | p.Lys415Glu | p.K415E | O95502 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-CG-5726-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| NPTXR | SNV | Missense_Mutation | rs375259496 | c.1061N>T | p.Ala354Val | p.A354V | O95502 | protein_coding | deleterious(0.02) | possibly_damaging(0.704) | TCGA-D7-A6EY-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 23467 | NPTXR | NA | NNZ-2566 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |